Fast moving Chinese regulators wave third homegrown PD-1 to market
Jiangsu Hengrui has secured an OK for its PD-1 drug, marking the fifth PD-1 approval in China and tilting the scale toward homegrown checkpoints.
Hengrui — a top 25 biopharma company globally led by Piaoyang Sun — joins Junshi and Innovent in facing foreign counterparts: Merck’s Keytruda and Bristol Myers’ Squibb’s Opdivo.
Its drug, camrelizumab, has long been tapped as one of the first finishers in China’s heated checkpoint race. Incyte dished out $25 million plus $770 million in biobucks to partner on its PD-1, although an odd adverse reaction diminished the American biotech’s enthusiasm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
